Subhead of release should read: Company to host a Conference
Call and Webcast on Wednesday, February 25th beginning at 10:00 a.m. EST
to report 4Q and FY2014 Financial Results (instead of Monday, February
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty
pharmaceutical company, today announced that based on a preliminary
review of 2014 fourth quarter results it expects Net Revenue to exceed
Project charge reduces second quarter earnings per share by $0.29 to $0.12 Exclusive of project charge, Company experiences strong margin performance across all segments Revenue increases from the first to second quarter lead to higher absorption of construction overhead costs Year-to-date project awards total $587.7 million excluding recently announced construction award for TransCanada's Napanee Generating Station
TULSA, Okla., Feb.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.